Hematologic Diseases: Clinical Trials

754 trials for Hematologic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

754 unknown. 754 Phase 2, 243 Phase 1, 79 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2754Unknown 754
Phase 1243Unknown 243
Phase 379Unknown 79

Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases

Trials (filtered) newest first · largest first

All 754 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP
corticosteroids combined with immunoglobulin and romiplostim - Primary Immune Thrombocytopenia
Phase 2UnknownUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology362024-11-202025-01-22
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
Dasatinib Pill, Ketoconazole Pill - Chronic Myeloid Leukemia, Chronic Phase
Phase 2UnknownHospital Universitario Dr. Jose E. Gonzalez152024-11-012022-12-06
Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
Pharmacoscopy, Clinical standard-of-care (physician's choice) - AML, Adult
Phase 2UnknownETH Zurich882024-09-022025-05-16
NAC for Hematopoietic Recovery in SAA
N Acetyl L Cysteine - Aplastic Anemia
Phase 2UnknownPeking University People's Hospital302024-07-252024-07-24
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
Inotuzumab ozogamicin - Acute Lymphoid Leukemia
Phase 2UnknownInstitute of Hematology & Blood Diseases Hospital, China212024-07-022024-07-30
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
DFP-10917, Venetoclax - Leukemia, Myeloid, Acute
Phase 1 / Phase 2UnknownDelta-Fly Pharma, Inc.392024-06-122025-09-03
PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)
Erythropoietin, blood transfusion - Anemia, Coronary Disease
Phase 2UnknownFederal University of São Paulo1202024-06-012024-08-07
A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP
Dexamethasone Combined with romiplostim N01, Dexamethasone monotherapy - Primary Immune Thrombocytopenia
Phase 2UnknownInstitute of Hematology & Blood Diseases Hospital, China1292024-06-012024-10-26
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
avatrombopag, Placebo - Thrombocytopenia, Stem Cell Transplant Complications
Phase 2 / Phase 3UnknownPeking University People's Hospital1422024-05-132024-10-01
Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Anti-BCMA CAR-NK - Multiple Myeloma, Refractory
Phase 1 / Phase 2UnknownShahid Beheshti University of Medical Sciences102024-04-302024-03-06
Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
ssCART-19, Fludarabine, Cyclophosphamide - Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2UnknownShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd502024-04-012024-04-19
PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
Thymoglobulin Injectable Product - Hematological Malignancy
Phase 2UnknownInstitut Paoli-Calmettes272024-03-312024-02-20
Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS
Fludarabine, Busulfan and Melphalan - Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2
Phase 2UnknownRuijin Hospital592024-03-032024-03-21
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
DEC3-VEN - Acute Myeloid Leukemia, Adult
Phase 2 / Phase 3UnknownThe Second Affiliated Hospital of Kunming Medical University402024-03-012024-02-29
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
Sirolimus, Abatacept, MMF - Acute Leukemia, Myelodysplastic Syndromes
Phase 1 / Phase 2UnknownPeking University People's Hospital62024-03-012024-03-21
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax - Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Phase 2UnknownFirst Affiliated Hospital of Zhejiang University342024-02-292024-05-30
Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade
Cyclophosphamid - Graft-versus-host Disease, Hematological Malignancies
Phase 2UnknownBeijing 302 Hospital222024-02-282024-02-20
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
CM313 injection - Multiple Myeloma
Phase 1 / Phase 2UnknownKeymed Biosciences Co.Ltd1202024-02-282023-11-13
Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA
Avatrombopag, Avatrombopag +rhTPO - Anemia, Aplastic
Phase 2UnknownInstitute of Hematology & Blood Diseases Hospital, China602024-02-012024-02-12
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
KQ-2003 CAR T-cells - Multiple Myeloma
Phase 1 / Phase 2UnknownNovatim Immune Therapeutics (Zhejiang) Co., Ltd.292024-01-112024-01-25

Showing 20 of 754. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (151)  ·  Multiple Myeloma (131)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (87)  ·  Myelodysplastic Syndromes (78)  ·  Leukemia (71)  ·  Lymphoma (53)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (47)  ·  Purpura, Thrombocytopenic, Idiopathic (44)  ·  Recurrence (41)  ·  Hematologic Neoplasms (40)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (30)  ·  Anemia, Aplastic (29)  ·  Anemia (26)  ·  Lymphoma, Large B-Cell, Diffuse (26)  ·  Lymphoma, Non-Hodgkin (26)

Broader conditions

Hemic and Lymphatic Diseases (754)  ·  Neoplasms (502)  ·  Neoplasms by Histologic Type (471)  ·  Immune System Diseases (362)  ·  Immunoproliferative Disorders (286)  ·  Lymphoproliferative Disorders (283)  ·  Leukemia (273)  ·  Pathological Conditions, Signs and Symptoms (219)  ·  Hemorrhagic Disorders (212)  ·  Pathologic Processes (209)  ·  Leukemia, Myeloid (189)  ·  Lymphatic Diseases (174)  ·  Cardiovascular Diseases (165)  ·  Vascular Diseases (163)

Interventions

Dexamethasone (69)  ·  Cyclophosphamide (55)  ·  Cytarabine (50)  ·  fludarabine (31)  ·  Bortezomib (30)  ·  Azacitidine (25)  ·  Busulfan (25)  ·  Lenalidomide (24)  ·  Decitabine (20)  ·  Melphalan (19)  ·  Rituximab (17)  ·  venetoclax (17)  ·  Methotrexate (16)  ·  Cyclosporine (15)  ·  Imatinib Mesylate (15)

Sponsors

Peking University People's Hospital (36)  ·  Nanfang Hospital, Southern Medical University (20)  ·  Institute of Hematology & Blood Diseases Hospital, China (19)  ·  The First Affiliated Hospital of Soochow University (17)  ·  Chinese PLA General Hospital (14)  ·  Shandong University (10)  ·  Sun Yat-sen University (10)  ·  Seoul National University Hospital (8)  ·  The University of Hong Kong (8)  ·  Chongqing Precision Biotech Co., Ltd (7)  ·  Federal Research Institute of Pediatric Hematology, Oncology and Immunology (7)  ·  Peking Union Medical College Hospital (7)  ·  Samsung Medical Center (7)  ·  Southwest Hospital, China (7)  ·  Ain Shams University (6)

Countries

China (281)  ·  United States (103)  ·  South Korea (47)  ·  Italy (41)  ·  Germany (40)  ·  France (37)  ·  United Kingdom (22)  ·  Russia (20)  ·  Israel (19)  ·  Spain (19)  ·  Belgium (16)  ·  Brazil (15)  ·  Poland (15)  ·  Netherlands (14)  ·  Canada (13)

Top investigators

Cheng Qian, PhD (7)  ·  Xiao-Hui Zhang, MD (7)  ·  Cheng Qian, MD, PhD (6)  ·  Qifa Liu, MD (6)  ·  Xiaohui Zhang, MD (6)  ·  Lei Zhang, MD (4)  ·  Sanbin Wang, MD (4)  ·  Xiao-Jun Huang (4)  ·  Yi Luo, M.D. (4)  ·  Arnon Nagler, MD (3)  ·  Evangelos Terpos, Prof (3)  ·  Hawk Kim, M.D., Ph.D. (3)  ·  Qifa Liu (3)  ·  Suzin Mayerson, PhD (3)

Results publications

PMID 34515338, PMID 28054442, PMID 20685256, PMID 23470153, PMID 24802773, PMID 25310303, PMID 29931453, PMID 35982483, PMID 40195173, PMID 41671463, PMID 10758304, PMID 11231246, PMID 11675328, PMID 11756187, PMID 12171484, PMID 12506176, PMID 12510709, PMID 14603333, PMID 15107815, PMID 15131807, PMID 15141377, PMID 15189396, PMID 15254053, PMID 15711856, PMID 15842354, PMID 16103468, PMID 16105981, PMID 16155013, PMID 16427380, PMID 16475046, PMID 16564913, PMID 16582916, PMID 16732175, PMID 17090654, PMID 17317857, PMID 17360989, PMID 17366834, PMID 17825602, PMID 17859247, PMID 18083847, PMID 18094721, PMID 18172005, PMID 18182574, PMID 18191732, PMID 18239868, PMID 18276714, PMID 18358930, PMID 18468541, PMID 18693069, PMID 18703664

NIH funding

2014 (7), 2018 (3), 2019 (3), 2009 (2), 2005 (1), 2015 (1), 2016 (1), 2017 (1), K12HL087165 (1), P01CA108671 (1), P30CA015704 (1), P30CA016042 (1), P30CA138292 (1), U54RR019397 (1)